Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

A new generative AI model rapidly generates diverse antimicrobial peptide structures for screening against ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

To offer further encouragement, Dame Emma Walmsley, the company’s chief, offered a more optimistic outlook than expected for ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare ...

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

Can-Fite’s lead drug candidate, Piclidenoson ... who will share insight into the Company’s current development pipeline and upcoming milestones. Strategically positioned with multiple out ...

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.